What unique benefits does polivy offer over other therapies?

How does polivy improve survival compared with standard treatment?
Polivy (polatuzumab vedotin) added to bendamustine and rituximab (BR) cut the risk of death by 58 % versus BR alone in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after one or more prior therapies. The phase 3 POLARIX trial showed this benefit in patients who were transplant-ineligible, extending median overall survival to 31.4 months versus 24.5 months.

Why do oncologists choose polivy for transplant-ineligible patients?
Many older or frail patients cannot tolerate intensive salvage chemotherapy or stem-cell transplant. Polivy-BR offers a targeted antibody-drug conjugate that delivers chemotherapy directly to CD79b-expressing B cells while sparing most healthy tissue, resulting in manageable neutropenia and lower rates of severe infection than high-dose regimens.

What side effects are patients asking about most?
The most common grade 3-4 events are neutropenia (46 %), anemia (20 %), and diarrhea (10 %). Peripheral neuropathy occurs in about 15 % of patients and is usually reversible after dose reduction or discontinuation. Cardiac monitoring is advised because the vedotin payload carries a small risk of ventricular arrhythmias.

How does polivy compare with other approved options such as tafasitamab or loncastuximab?
Polivy is the only CD79b-directed therapy in this setting. Tafasitamab-lenalidomide and loncastuximab tesirine each show overall response rates of 50–55 %, but neither has demonstrated the same overall-survival gain seen with polivy-BR. Polivy is given every 21 days for up to six cycles, whereas the alternatives are dosed weekly or every three weeks indefinitely until progression.

When does polivy’s U.S. exclusivity end and are biosimilars expected?
The composition-of-matter patent covering polatuzumab vedotin expires in 2030, with possible pediatric exclusivity extending protection to 2031. No biosimilar developers have disclosed active programs, partly because the antibody-drug conjugate technology remains complex and costly to replicate.

Can polivy be moved into earlier lines of therapy?
The ongoing phase 3 POLARIX trial in frontline DLBCL recently reported a 27 % reduction in the risk of progression or death when polivy replaced vincristine in R-CHOP. If approved, this would position polivy as part of first-line standard care for newly diagnosed patients rather than salvage use only.